Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1998-02-12
2002-08-13
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000
Reexamination Certificate
active
06432937
ABSTRACT:
FIELD OF THE INVENTION
The present invention provides a new treatment for joint inflammation.
BACKGROUND TO THE INVENTION
The symptoms of joint inflammation are generally associated with spondyloarthropathies (for example ankylosing spondylitis, psoriatic arthropathy, reactive arthritides and sacroiliitis) and rheumatoid arthritis. The joint inflammation is localised to different joints in these different conditions. In ankylosing spondylitis the inflammation is localised to the spine, the sacroiliac joints, and also often to the peripheral large joints (e.g. the knees, elbows and ankles). In sacroiliitis the inflammation is isolated to the sacroiliac joints but sometimes occurs in the peripheral joints as well. The other spondyloarthropathies have a similar clinical picture so far as which joints are inflamed. In rheumatoid arthritis a symmetrical joint inflammation occurs.
Rheumatoid arthritis and the spondyloarthropathies have in common a chronic inflammation of the synovial and extrasynovial structures such as the tendons and ligaments. The inflammatory reaction of the joints is dominated by certain inflammatory cells (for example neutrophils, activated lymphocytes and macrophages) which all contribute to the joint pain and the destruction of the joints.
The drugs which have in the past been used to treat joint inflammation are based on symptomatic anti-inflammatory treatments or disease modifying treatments. The dominating drugs for symptomatic treatments are non-steroidal anti-inflammatory drugs, orally active glucocorticosteroids with a mainly systemic effect or intraarticular injections of glucocorticosteroids. The disease modifying treatments include drugs which, by influencing the immune reactions of the body, reduce joint inflammation. Examples of disease modifying drugs include methotrexate, azathioprine, gold salts, cyclophosphamide and sulphasalazine. All of these treatments unfortunately cause severe side effects and are not particularly effective. For example glucocorticoid administration is generally directed against the local inflammation, i.e. it has been used to treat directly the inflammatory cells present in the joint inflammation. The routes used to administer such glucocorticoid treatment results in severe side effects on the body including effects on the skeleton and muscles.
It has now surprisingly been found that oral or rectal administration of a glucocorticoid substance which has a minimal systemic effect is effective in controlling the joint inflammation.
SUMMARY OF THE INVENTION
According to the invention there is provided the use of a glucocorticoid substance which has a minimal systemic effect in the manufacture of a medicament for oral or rectal administration for non-topical use in the treatment of joint inflammation.
According to the invention there is further provided a method of treating a human or non-human mammal suffering from joint inflammation which comprises administering non-topically and orally or rectally to the human or non-human mammal a therapeutically effective amount of a glucocorticoid substance which has a minimal systemic effect.
According to the invention there is also provided a pharmaceutical composition comprising a glucocorticoid substance which has a minimal systemic effect in association with a pharmaceutically acceptable diluent, adjuvant or carrier, which composition is for non-topical use in the treatment of joint inflammation.
REFERENCES:
patent: 5482934 (1996-01-01), Calatayud et al.
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5889049 (1999-03-01), Juergens
patent: 0 502 092 (1995-07-01), None
patent: 0502092 (1995-07-01), None
T.H.J. Florin et al., “Is the Arthritis of Crohn's Disease Due to Intestinal Disease,” Abstract of the 4thUnited, European Gastroenterology Week, Sep. 17-21, 1995, Berlin, Germany.
Jiri Mestecky et al., “Mucosal Immunity in the Female Genital Tract: Relevance to Vaccination Efforts against the Human Immunodeficiency Virus,” Aids Research and Human Retroviruses, vol. 10, Supplement 2, 1994, pp. S11-S20.
Thomas B. Tomasi, “Introduction: An Overview of the Mucosal System,” Handbook of Mucosal Immunology, 1994, pp. 3-8.
Per Brandtzaeg, “Basic Mechanisms of Mucosal Immunity—A Major Adaptive Defense System,” The Immunologist, 3/3 (1995), pp. 89-96.
Journal of Computer Assisted Tomography, vol. 20, No. 4, 1996, Matthias Bollow et al., “CT-Guided Intraarticular Corticosteroid Injection into the Sacroiliac Joints in Patients with Spondyloarthropathy: Indication and Follow-Up with Contrast-Enhanced MRI”, pp. 512-521.
Journal of rheumatology, vol. 22, No. 9, 1995, Daniel J. McCarty et al., “Treatment of Rheumatoid Joint Inflammation with Intrasynovial Triamcinolone Hexacetonide”, pp. 1631-1635.
The Journal of Rheumatology, vol. 10, No. 3, 1983, Gary D. Sladek et al., “Beclomethasone dipropionate in the treatment of the rheumatoid larynx”, pp. 518-519.
Astra Aktiebolag
Criares Theodore J.
Fish & Richardson P.C.
LandOfFree
Treatment for joint inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for joint inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for joint inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2953659